

DIAGNOSIS:


Secretory carcinoma.

DISCUSSION:

In the era of precision medicine, the identification of several predictive biomarkers and the development of innovative therapies have dramatically increased the request of tests to identify specific targets on cytological or histological samples.

Chromosomal translocations involving the NTRK1, NTRK2, and NTRK3 genes result in constitutive activation and aberrant expression of TRK kinases in numerous cancer types (Fig 9).⁵

In this context, the identification of tumors harboring TRK fusions is crucial. Several



(Fig 9. Spectrum of adult and pediatric tumors harboring NTRK gene fusions.)